- United States
- /
- Life Sciences
- /
- NYSE:TMO
Weekly Picks: š 3 stocks that could thrive during stagflation
Welcome to Weekly Picks, where each week our analysts hand pick their favourite Narratives from the community (Ā what is a Narrative? ).
Thereās been a lot of talk about āstagflationā recently. Our latest Market Insights piece goes into plenty of detail and how to thrive during it, but it's well known that, historically speaking, it can be a rough period for stocks in general.Ā
For example, during the stagflation of the 1970's, a major index like the Dow Jones went virtually nowhere for 10 years.
However... there were a handful of industries that actually delivered outsized returns during that period. ššø Investors who knew where to look during that period actually faired pretty well!
Some of those industries they did well with, amongst others, were healthcare, commodity producers and gold miners.
So, with that risk possibly on the horizon, this weekās picks cover:
- š Why Thermo Fisher is well positioned to maintain its leadership in life sciences
- šŖØ How Rio Tintoās diversification strategy could reduce risk but lower margins
- āļø Why Hochschild Mining has huge potential if gold and silver keep climbing.
What's next?
-
š Know when to act: Set the narrative valuations as your own fair value to know when to buy, hold or sell the stock.
-
š¤ Get answers: Ask the author any questions in the comments section. Feel free to like as well to support their work.
-
⨠Discover more Narratives: There are hundreds of other insightful stock narratives on our Community page .
-
āļø Build an audience: Have your narrative seen by millions of investors, simply meet our Featuring criteria to go into the running!
Valuation is complex, but we're here to simplify it.
Discover if Thermo Fisher Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Michael Paige and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Michael Paige
Michael is the Content Lead at Simply Wall St. With over 9 years of experience analysing and researching companies, Michael contributes to the creation of our analytical content and has done so as an equity analyst since 2020. He previously worked as an Associate Adviser at Ord Minnett, helping build and manage clients' portfolios, and has been investing personally since 2015.
About NYSE:TMO
Thermo Fisher Scientific
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
Very undervalued with acceptable track record.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced DeepāTech Inflection Point With MultiāBillionāDollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives
Guidance Cuts and AI Concerns Shake S&P Global
VRSK 05-2026
Long earnings, cautious on multiple
Popular Narratives
QuantumScape: A Mispriced DeepāTech Inflection Point With MultiāBillionāDollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years

